-
Product Insights
Middle East Respiratory Syndrome (MERS) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Middle East Respiratory Syndrome (MERS) Pipeline Drugs Market Report Overview Middle East respiratory syndrome (MERS) is a viral respiratory disease caused by a coronavirus (MERS-CoV). Symptoms include fever, cough, and shortness of breath. Other symptoms include nausea, vomiting and diarrhea. The MERS pipeline drugs market research report provides comprehensive information on the MERS targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also reviews key players...
-
Product Insights
Net Present Value Model: Avigan
Overview Evaluating the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the market currently and in the future, knowledge of cash inflows and outflows and the potential success rates for each stage of drug development. GlobalData has done all of this work for you, leveraging its gold standard Drugs Intelligence database to create high-value NPV models for purchase on a drug-by-drug basis. Drug Operating Profit Model Avigan Drug Details Favipiravir (Avigan) is...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – INO-4500
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry INO-4500 Drug Details INO-4500 is under development for the prevention of lassa fever. The...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – lassa fever vaccine
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry lassa fever vaccine Drug Details Vaccine candidate is under development for the prevention of...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – EBS-Lassa
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry EBS-Lassa Drug Details Vaccine is under development for the prevention of lassa hemorrhagic fever....
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – GBV-006
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry GBV-006 Drug Details GBV-006 is under development for the treatment of dengue infection, Hantavirus...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – LHF-535
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry LHF-535 Drug Details LHF-535 is under development for the treatment of arenaviridae infection and...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – favipiravir
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry favipiravir Drug Details Favipiravir (Avigan) is an antiviral agent. It is formulated as tablets...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – AMG-634
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry AMG-634 Drug Details AMG-634Â is under development for the treatment of tuberculosis, erythema nodosum leprosum...
-
Product Insights
Lassa Fever (Lassa Hemorrhagic Fever) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Lassa Fever (Lassa Hemorrhagic Fever) pipeline market research report provides comprehensive information on the therapeutics under development for Lassa Fever (Lassa Hemorrhagic Fever), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for...